Agenus BOTBAL survival data challenges expectations in MSS metastatic colorectal cancer
Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.
Pharma & Biotech
Pharma & Biotech
Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test
Read how Agenus’ three-year BOT+BAL survival update could reshape expectations in refractory MSS metastatic colorectal cancer.
Pharma & Biotech
Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
Pharma & Biotech
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
Pharma & Biotech
Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
Read how Agenus’ AACR 2026 data could reshape treatment sequencing in refractory gastroesophageal cancer and what risks still matter.
Pharma & Biotech
What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
Pharma & Biotech
What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
Pharma & Biotech
How Agenus is taking aim at cold tumors with Fc-enhanced anti-CTLA-4 therapy
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.